Brief: Invion Ltd Announces Agreement With Major South Korean Pharma Group Hanlim
May 8 (Reuters) - Invion Ltd IVX.AX :
* AGREEMENT WITH MAJOR SOUTH KOREAN PHARMA GROUP HANLIM
* HANLIM TO UNDERTAKE AND FUND EVALUATION PROOF-OF-CONCEPT
IN VIVO
STUDIES ON EFFICACY OF INV043 ON GLIOBLASTOMA MULTIFORME
Further company coverage: IVX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invion
See all newsAustralia's Invion rises after securing clinical trial funding arrangements
Brief: Invion Ltd Says Funding Agreements Cover Up To 85% Of Clinical Trials Costs
Brief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Australia's Invion enters ophthalmology agreement with Sangmyung Innovation
Brief: Invion Signs First Ophthalmology Collaboration Agreement With Sangmyung Innovation